Gary Wilkinson

1.1k citations

23 papers · 546 indexed · h-index 10

Impact in

Oncology
- PARP inhibition in cancer therapy
Hematology

Papers in ⓘ

Molecular Biology 15
- DNA Repair Mechanisms 5
- Cancer therapeutics and mechanisms 3
- Protein Degradation and Inhibitors 2
Oncology 7
- PARP inhibition in cancer therapy 3
- Cancer-related Molecular Pathways 3
- Cancer Treatment and Pharmacology 2

Co-authors: Thomas M. McGuire (2 shared papers)Sylvie M. Guichard (2 shared papers)Rajesh Odedra (2 shared papers)Christine Wood (2 shared papers)Kevin M. Foote (2 shared papers)James Yates (2 shared papers)Philip J. Jewsbury (2 shared papers)Kevin Blades (2 shared papers)
Journals: Cancer Research (3 papers)European Journal of Cancer (3 papers)MedChemComm (3 papers)Journal of Clinical Oncology (2 papers)British Journal of Pharmacology (2 papers)
Partner nations: United Kingdom United States Germany

In The Last Decade

Gary Wilkinson

21 papers receiving 536 citations

Peers

Countries citing papers authored by Gary Wilkinson

Since Specialization

Citations

This map shows the geographic impact of Gary Wilkinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Wilkinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Wilkinson more than expected).

Fields of papers citing papers by Gary Wilkinson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Wilkinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Wilkinson. The network helps show where Gary Wilkinson may publish in the future.

Co-authors

The 25 scholars most cited alongside Gary Wilkinson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gary Wilkinson Line = papers co-authored together Gary Wilkinson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent Journal of Medicinal Chemistry ·Kevin M. Foote, J. Willem M. Nissink, Thomas M. McGuire, Paul Turner, Sylvie M. Guichard, James Yates, Alan Lau, Kevin Blades, Dan Heathcote, Rajesh Odedra, Gary Wilkinson, Zena Wilson, Christine Wood, Philip J. Jewsbury	2018	225
2	Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies European Journal of Drug Metabolism and Pharmacokinetics ·Christian Zurth, Mikko Koskinen, Robert E. Fricke, Olaf Prien, Timo Korjamo, Kristina Graudenz, Karsten Denner, Michaela Bairlein, Clemens-Jeremias von Bühler, Gary Wilkinson, Hille Gieschen	2019	71
3	First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity European Journal of Cancer ·Sophie Postel‐Vinay, Karin H. Herbschleb, Christophe Massard, Victoria K. Woodcock, Jean‐Charles Soria, Annette O. Walter, Flavio Ewerton, Martine Poelman, Neil Benson, Matthias Ocker, Gary Wilkinson, Mark R. Middleton	2019	70
4	Abstract 2348: Discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients. Cancer Research ·Clifford D. Jones, Kevin Blades, Kevin M. Foote, Sylvie M. Guichard, Philip J. Jewsbury, Thomas M. McGuire, Johannes W. Nissink, Rajesh Odedra, Kin Yip Tam, Pia Thömmes, Paul Turner, Gary Wilkinson, Christine Wood, James Yates	2013	29
5	First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. Journal of Clinical Oncology ·Johann S. de Bono, David S.P. Tan, Reece Caldwell, Angelika Terbuch, Boon Cher Goh, Valerie Heong, Noor Md Haris, Saira Bashir, David S. Hong, Funda Meric‐Bernstam, Sonal Bordia, Li Liu, Gary Wilkinson, Joseph Hreiki, Antje M. Wengner, Kerstin Fischer, Oliver Boix, Eleni Lagkadinou, Elizabeth Ruth Plummer, Timothy A. Yap	2019	25
6	Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent Investigational New Drugs ·Gary Wilkinson, James P. Taylor, Steven D. Shnyder, Patricia A. Cooper, Phil W. Howard, David E. Thurston, Terence C. Jenkins, Paul M. Loadman	2004	18
7	First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies European Journal of Cancer ·Sophie Postel‐Vinay, Karin H. Herbschleb, Christophe Massard, Victoria K. Woodcock, Matthias Ocker, Gary Wilkinson, Annette O. Walter, Flavio Ewerton, Martine Poelman, Michael S. Middleton, J.C. Soria	2016	14
8	Discovery of a series of 2-(pyridinyl)pyrimidines as potent antagonists of GPR40 MedChemComm ·Michael J. Waring, David Baker, Stuart N. L. Bennett, Alexander G. Dossetter, Mark L. Fenwick, Rob Garcia, Jennie Georgsson, Sam D. Groombridge, Susan J. G. Loxham, Philip A. MacFaul, Katie G. Maskill, David Morgan, Jenny Morrell, Helen Pointon, Graeme R. Robb, David M. Smith, S.P. Stokes, Gary Wilkinson	2015	11
9	Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment Clinical Pharmacokinetics ·Christian Zurth, Pirjo Nykänen, Gary Wilkinson, Päivi Taavitsainen, Annamari Vuorela, Funan Huang, Susanne Reschke, Mikko Koskinen	2021	10
10	Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy Cancers ·Andreas Schneeweiß, Dagmar Hess, Markus Joerger, Andréa Varga, Stacy Moulder, Apostolia M. Tsimberidou, X. Cynthia, Sara A. Hurvitz, Christine Rentzsch, Marion Rudolph, Silke Thiele, Oliver Boix, Gary Wilkinson, Eleni Lagkadinou, Matthias Ocker	2019	10
11	Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: Results from clinical and in vitro studies. Journal of Clinical Oncology ·Christian Zurth, Kristina Graudenz, Karsten Denner, Timo Korjamo, Robert E. Fricke, Gary Wilkinson, Friedeborg Seitz, Olaf Prien	2019	9
12	Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes British Journal of Pharmacology ·David Baker, A M Atkinson, Gary Wilkinson, Gareth Coope, Alison Charles, Brendan Leighton	2013	9
13	Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes British Journal of Pharmacology ·David Baker, Gary Wilkinson, A M Atkinson, H. B. Jones, Matthew P. Coghlan, Alison Charles, Brendan Leighton	2013	9
14	Abstract CT006: Phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with DNA damage response (DDR) defects Cancer Research ·Timothy A. Yap, David S.P. Tan, Anastasios Stathis, Geoffrey I. Shapiro, Satoru Iwasa, Markus Joerger, Jingsong Zhang, Ruth Plummer, Michael B. Sawyer, Aaron C. Tan, Vincent Castonguay, Nashat Gabrail, Nobuaki Matsubara, Gary Wilkinson, Matthias Ludwig, Yinghui Zhou, Claudia Merz, Joseph Hreiki, Neelesh Sharma, Johann S. de Bono	2022	8
15	Optimising pharmacokinetics of glucokinase activators with matched triplicate design sets – the discovery of AZD3651 and AZD9485 MedChemComm ·Michael J. Waring, Stuart N. L. Bennett, Scott Boyd, Leonie Campbell, Robert D. M. Davies, David Hargreaves, Philip A. MacFaul, Nathaniel G. Martin, D. Ogg, Graeme R. Robb, Gary Wilkinson, J. Matthew Wood	2013	6
16	Matched triplicate design sets in the optimisation of glucokinase activators – maximising medicinal chemistry information content MedChemComm ·Michael J. Waring, Stuart N. L. Bennett, Scott Boyd, Leonie Campbell, Robert D. M. Davies, S. Gerhardt, David Hargreaves, Nathaniel G. Martin, Graeme R. Robb, Gary Wilkinson	2013	6
17	Impaired elimination of meperidine in patients with liver disease. PubMed ·McHorse Ts, Ulrich Klotz, Gary Wilkinson, S. Schenker	1974	6
18	First-in-Human Dose-Escalation Study of the First-in-Class PDE3A–SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A Clinical Cancer Research ·Kyriakos P. Papadopoulos, Meredith McKean, Silvia Goldoni, Isabelle Genvresse, Marine F. Garrido, Rui Li, Gary Wilkinson, Christoph Kneip, Timothy A. Yap	2024	3
19	Optimization of treatment schedule for the ATR inhibitor elimusertib (BAY 1895344) in preclinical tumor models European Journal of Cancer ·Antje M. Wengner, Lisa Ehresmann, Nils Guthof, S. Osterberg, Bart A. Ploeger, A. Wiedmann, Gary Wilkinson	2022	3
20	The use of gold as a therapeutic agent in small-animal practice Veterinary Record ·Gary Wilkinson	1951	3

About Gary Wilkinson

Gary Wilkinson is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Hematology and Surgery, having authored 23 papers that have together received 546 indexed citations. Recurring topics across this work include DNA Repair Mechanisms (5 papers), Pancreatic function and diabetes (3 papers), Cancer therapeutics and mechanisms (3 papers), PARP inhibition in cancer therapy (3 papers), Prostate Cancer Treatment and Research (3 papers), Cancer-related Molecular Pathways (3 papers), Cancer Treatment and Pharmacology (2 papers) and Protein Degradation and Inhibitors (2 papers). The work is most often cited by research in Oncology (179 citations), Hematology (55 citations), Molecular Biology (327 citations), Organic Chemistry (125 citations) and Cancer Research (45 citations). Gary Wilkinson has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Thomas M. McGuire, Sylvie M. Guichard, Rajesh Odedra, Christine Wood, Kevin M. Foote, James Yates, Philip J. Jewsbury, Kevin Blades, Paul Turner and Dan Heathcote. Their work appears in journals such as Cancer Research, European Journal of Cancer, MedChemComm, Journal of Clinical Oncology and British Journal of Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact